Rijnders, Maud
Nakauma-González, J. Alberto http://orcid.org/0000-0002-9153-4280
Robbrecht, Debbie G. J. http://orcid.org/0000-0003-2490-9991
Gil-Jimenez, Alberto http://orcid.org/0000-0003-0643-6676
Balcioglu, Hayri E. http://orcid.org/0000-0002-0225-0180
Oostvogels, Astrid A. M.
Aarts, Maureen J. B.
Boormans, Joost L. http://orcid.org/0000-0002-5127-0436
Hamberg, Paul
van der Heijden, Michiel S. http://orcid.org/0000-0002-4407-7881
Szabados, Bernadett E.
van Leenders, Geert J. L. H. http://orcid.org/0000-0003-2176-9102
Mehra, Niven http://orcid.org/0000-0002-4794-1831
Voortman, Jens http://orcid.org/0000-0001-8309-2614
Westgeest, Hans M. http://orcid.org/0000-0002-5735-3638
de Wit, Ronald
van der Veldt, Astrid A. M.
Debets, Reno http://orcid.org/0000-0002-3649-807X
Lolkema, Martijn P. http://orcid.org/0000-0003-0466-2928
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (848050012)
Merck Sharp & Dohme
Article History
Received: 17 June 2022
Accepted: 1 February 2024
First Online: 14 February 2024
Competing interests
: M.P.L. has received research support from JnJ, Sanofi, Astellas and MSD, and consultancy fees from Incyte, Amgen, JnJ, Bayer, Servier, Roche, INCa, Pfizer, Sanofi, Astellas, AstraZeneca, Merck Sharp & Dohme, Novartis, Julius Clinical and the Hartwig Medical Foundation (all paid to the Erasmus MC Cancer Institute). D.G.J.R. has received research support from Treatmeds and consultancy fees from Bristol-Myers Squibb, Bayer, AstraZeneca, Merck, Pfizer (all paid to the Erasmus MC Cancer Institute). R.d.W. has received consultancy fees from Sanofi, Merck, Astellas, Bayer, Hengrui and Orion, speaker fees from Sanofi and Astellas, research support from Sanofi and Bayer (all paid to the Erasmus MC Cancer Institute). A.A.M.v.d.V. has received consultancy fees from for BMS, MSD, Merck, Novartis, Roche, Sanofi, Pierre Fabre, Ipsen, Eisai, Pfizer (all paid to the Erasmus MC Cancer Institute). M.S.v.d.H. has received research support from Bristol-Myers Squibb, AstraZeneca and Roche, and consultancy fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, AstraZeneca, Seattle Genetics and Janssen (all paid to the Netherlands Cancer Institute). J.L.B. has received research support from Decipher Biosciences and Merck Sharp & Dohme, and consultancy fees from Merck Sharp & Dohme, Eight Medical, Ambu, APIM therapeutics, Bristol-Myers Squibb, Astellas Roche and Janssen (all paid to the Erasmus MC Cancer Institute). N.M. has received research support from Astellas, Janssen, Pfizer, Roche and Sanofi Genzyme, and consultancy fees from Roche, MSD, BMS, Bayer, Astellas and Janssen (all paid to the Radboud University Medical Center). H.M.W. has received consultancy fees from Roche and Astellas (all paid to the Amphia hospital, Breda). P.H. has received consultancy fees from Astellas, Merck Sharp & Dohme, Pfizer AstraZeneca, Bristol-Myers Squibb and Ipsen (all paid to the Franciscus Gasthuis & Vlietland Hospital, Rotterdam/Schiedam). M.J.B.A. has received advisory board/consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer, research grants from Merck-Pfizer (all paid to Maastricht UMC+ Comprehensive Cancer Center). G.J.L.H.v.L. has received research grants from Roche and AstraZenaca, and has been member of advisory boards of Roche and Merck (all paid to the Erasmus MC Cancer Institute). R.D. has received research support from MSD and Bayer, personal fees from Bluebird Bio, Genticel, other support from Pan Cancer T outside the submitted work (all paid to the Erasmus MC Cancer Institute), and is listed as inventor for European patent application nos. 21152822.9 and 21184727.2 (pending to Erasmus MC). M.R., J.A.N.-G., A.G.-J., J.V., A.A.M.O. and H.E.B. declare no competing interests.